COVID-19 Vaccine for Coronavirus
(COVID-19 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.
Who Is on the Research Team?
Clinical Development
Principal Investigator
Novavax, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- NVX-CoV2705
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
a single intramuscular (IM) injection of NVX-CoV2705 on Day 0
a single intramuscular (IM) injection of placebo (normal saline) on Day 0
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novavax
Lead Sponsor
Sanofi
Industry Sponsor
Paul Hudson
Sanofi
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Christopher Corsico
Sanofi
Chief Medical Officer
MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.